JOEL MEYER: Open Payments
NPI 1578326203 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$258 in 17 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $239 · 2025 $258
Food & beverage: $258
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $49 |
| Lilly USA, LLC | 3 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| PFIZER INC. | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
| Merck Sharp & Dohme LLC | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Amgen Inc. | 1 | $15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
Products named: JARDIANCE, MOUNJARO, VOQUEZNA, Wegovy, PREVNAR 20, AIRSUPRA, XIFAXAN, PROQUAD.
Industry payments across NE — which companies pay providers there.
